Gene Techno Science (4584) Stock Overview

Kidswell Bio Corporation develops pharmaceuticals for the treatment of rare and intractable diseases in Japan. Its pipeline products include GND-004 for the treatment of ophthalmic disease and oncology; GND-007 for the treatment of immunological disease; and antibodies for oncology. The company pipeline products also include GBS-001, GBS-004, and GBS-010 for oncology; GBS-005 for immunological diseases; GBS-007 and GBS-012 for ophthalmic disease; GBS-008 for infectious diseases; and GBS-011 for renal disease. In addition, its products also include GCT-101 for alveolar cleft; GCT-102 for congenital isolated hypoganglionosis; and other pipeline products for ophthalmologic diseases, cerebral palsy, peripheral nerve palsy, fracture, and spinal cord injury. The company was formerly known as Gene Techno Science Co.,Ltd. and changed its name to Kidswell Bio Corporation in July 2021. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.

4584 Stock Information

Symbol

4584

Address

Kanayama BuildingTokyo, 104-0033Japan

Founded

Trading hours

Website

https://www.kidswellbio.com

Country

🇯🇵 Japan

Phone Number

81 3 6222 9547

Gene Techno Science (4584) Price Chart

Gene Techno Science Overview: Key Details and Summary

Stock data	2023	Change
Price	$0.9376627235518165	N/A
Market Cap	$29.68M	N/A
Shares Outstanding	31.65M	2.60%
Employees	38.00	N/A
Shareholder Equity	1.23B	-27.56%

Valuation	2023	Change
P/E Ratio	-0.05	N/A
P/S Ratio	1.54	N/A
P/B Ratio	0.02	N/A

Growth	2023	Change
Return on Equity	-0.0037	N/A

Earnings	2023	Change
Revenue	$19.28M	N/A
Earnings	-$4.57M	N/A
EPS	-20.77	N/A
Earnings Yield	-22.15	N/A
Gross Margin	0.5496	N/A
Operating Margin	-0.1984	N/A
Net income margin	-0.2368	N/A

Financial Strength	2023	Change
Total Assets	$27.05M	N/A
Total Debt	$13.54M	N/A
Cash on Hand	$7.41M	N/A
Debt to Equity	0.0150	107.87%
Cash to Debt	0.5473	-67.00%
Current Ratio	$3.50	18.09%